A fully integrated specialty pharmaceutical company with industry-leading transdermal expertise
Noven’s preliminary product in the mental health sector is DAYTRANA® (methylphenidate transdermal system), the first and only transdermal system approved for ADHD in children and adolescents ages 6-17. DAYTRANA is marketed by Noven Therapeutics.
SECUADO® (asenapine) transdermal system, the first and only antipsychotic delivered through patch technology in the United States for the treatment of schizophrenia in adults, has been added to the Noven mental health portfolio. SECUADO is applied once daily and is available in three dosage strengths.